(Q46902730)

26 December 2017

title

Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women (English)

1 reference

26 December 2017

0 references

1 reference

V Rabenda

1

1 reference

26 December 2017

R Mertens

2

1 reference

26 December 2017

V Fabri

3

1 reference

26 December 2017

J Vanoverloop

4

1 reference

26 December 2017

F Sumkay

5

1 reference

26 December 2017

C Vannecke

6

1 reference

26 December 2017

A Deswaef

7

1 reference

26 December 2017

G A Verpooten

8

1 reference

26 December 2017

J Y Reginster

9

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

26 December 2017

Osteoporosis International

published in

1 reference

26 December 2017

volume

19

1 reference

26 December 2017

issue

6

1 reference

26 December 2017

page(s)

811-818

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1007/s00198-007-0506-x

exact match

0 references

cites work

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Compliance with pharmacologic therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

The impact of compliance with osteoporosis therapy on fracture rates in actual practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Patients with osteoporosis prefer once weekly to once daily dosing with alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Persistence with weekly alendronate therapy among postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

The use of claims databases for outcomes research: rationale, challenges, and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Identification of fractures from computerized medicare files

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Compliance with drug therapies for the treatment and prevention of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

The assessment of refill compliance using pharmacy records: methods, validity, and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Assessment of compliance with osteoporosis treatment and its consequences in a managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0506-X

Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment

21 January 2018

1 reference

12 December 2020

Estimating medication persistency using administrative claims data.

1 reference

12 December 2020

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

1 reference

12 December 2020

The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women

1 reference

12 December 2020

Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover

1 reference

12 December 2020

Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women

1 reference

12 December 2020

10.1007/S00198-007-0506-X

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017